B W Blakley1. 1. Department of Otolaryngology, University of Manitoba, Winnipeg, Canada. BBLAKLEY@EXCHANGE.HSC.MB.CA
Abstract
OBJECTIVE: To review the literature relating to intratympanic gentamicin injection therapy for Meniere's disease to detect consistencies and differences that might suggest optimal technique. DESIGN: Retrospective literature review. METHODS: Eighteen papers from the literature regarding clinical experience with intratympanic gentamicin injections for treatment of Meniere's disease were reviewed and tabulated. RESULTS: All papers reported high success rates in treating episodic vertigo of Meniere's disease, but technique, dose, duration, and treatment philosophy varied considerably. Hearing loss was typically reported in about 30% of patients. CONCLUSION: No single technique of gentamicin injection has a significant medical advantage over the others. Until controlled studies indicate otherwise, nonmedical needs such as convenience and safety may be considered when choosing a technique.
OBJECTIVE: To review the literature relating to intratympanic gentamicin injection therapy for Meniere's disease to detect consistencies and differences that might suggest optimal technique. DESIGN: Retrospective literature review. METHODS: Eighteen papers from the literature regarding clinical experience with intratympanic gentamicin injections for treatment of Meniere's disease were reviewed and tabulated. RESULTS: All papers reported high success rates in treating episodic vertigo of Meniere's disease, but technique, dose, duration, and treatment philosophy varied considerably. Hearing loss was typically reported in about 30% of patients. CONCLUSION: No single technique of gentamicin injection has a significant medical advantage over the others. Until controlled studies indicate otherwise, nonmedical needs such as convenience and safety may be considered when choosing a technique.
Authors: Frank R Lin; Americo A Migliaccio; Thomas Haslwanter; Lloyd B Minor; John P Carey Journal: Ann Otol Rhinol Laryngol Date: 2005-10 Impact factor: 1.547
Authors: Erin E Leary Swan; Mark J Mescher; William F Sewell; Sarah L Tao; Jeffrey T Borenstein Journal: Adv Drug Deliv Rev Date: 2008-09-21 Impact factor: 15.470